Skip to main content
Top
Published in: Cancer Immunology, Immunotherapy 5/1997

01-01-1997 | ORIGINAL ARTICLE

Treatment of human lung carcinoma xenografts with a combination of 131I-labelled monoclonal antibody Po66 and doxorubicin

Authors: B. Desrues, F. Brichory, H. Léna, P. Bourguet, P. Delaval, L. Toujas, L. Dazord

Published in: Cancer Immunology, Immunotherapy | Issue 5/1997

Login to get access
Metadata
Title
Treatment of human lung carcinoma xenografts with a combination of 131I-labelled monoclonal antibody Po66 and doxorubicin
Authors
B. Desrues
F. Brichory
H. Léna
P. Bourguet
P. Delaval
L. Toujas
L. Dazord
Publication date
01-01-1997
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 5/1997
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s002620050333

Other articles of this Issue 5/1997

Cancer Immunology, Immunotherapy 5/1997 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine